39 results about "Cell recruitment" patented technology

Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.

Methods and apparatus are disclosed for treating congestive heart failure. The method includes relieving wall stress on a diseased heart by an amount to decrease a rate of myocardial cell loss. Further, the method includes pharmacologically encouraging a myocardial cell gain. Cell gain may be encouraged by cell replication, cell recruitment or inhibition of cell death. Further embodiments of the method include a passive cardiac constraint selected to reduce wall stress on the heart. An apparatus of the present invention includes a passive cardiac constraint and a pharmacological agent to encourage cell gain.

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Polypeptides are provided that bind CD123 on a target cell and the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of CD123 associated cancers or inflammatoryconditions.

The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment andimmune signal delivery function.

The instant invention is based, at least in part, on the discovery that T-bet controls ThI cell recruitment to sites of inflammation. This invention pertains to, inter alia, methods of identifying agents that modulate the effects of T-bet on the recruitment of T cells to sites of inflammation by modulating P-selectin-mediated T cell rolling and / or stable adherence of a T cell to a vascular endothelial cell, as well as methods of use therefore.

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

The invention discloses a bispecific antibody for multiple myeloma and its application, and belongs to the technical field of genetic engineering antibodies. In the present invention, the antibody F00 targeting human BCMA and the antibody D00 targeting human PD-1 are used as parent antibodies, and 'knob' and 'hole' ends are respectively introduced into the two heavy chain Fc according to the CrossMab platform using genetic engineering technology. Animal eukaryotic expression system expresses DF00. The present invention also provides a method for expressing and purifying the bispecific antibody DF00. The target protein is obtained by secreting expression of HEK293 cells and purifying by affinity chromatography. The bispecific antibody DF00 can specifically bind to both the BCMA molecule on the surface of multiple myeloma (MM) cells and the immune checkpoint molecule PD-1 on the surface of activated T cells, inhibiting the immunosuppressive microenvironment in tumors and promoting T cells Recruited to surrounding multiple myeloma cells, remodeling the function of T cells to kill MM cells.

The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.

The present invention relates to a conditionally bispecific redirected activation construct or COBRA administered in the form of an active prodrug. Upon exposure to a tumor protease, the constructs are cleaved and activated such that they are able to bind both tumor target antigens (TTAs) and CD3, thereby recruiting CD3-expressing T cells to the tumor for treatment. In some embodiments, the tumor target antigen is B7H3.

The present invention relates to a fibrous wound repair scaffold loaded with phase change material particles, and a preparation method and application thereof. The invention uses aliphatic polyester, natural macromolecules and phase change materials as main raw materials, adds antibacterial drugs, active substance particles and growth factors, and prepares a multi-layered scaffold with biological activity through electrospinning, electrostatic spraying and the like. The fiber wound repair scaffold provided by the invention adds different kinds of antibacterial drugs to achieve multiple antibacterial effects; contains biologically active substance particles with increased deposition density gradient to promote cell recruitment and migration; contains phase change material particles that promote repair growth factors, To modulate the behavior of different cells by photothermally-triggered controllable delivery of growth factors. The scaffold material provided by the invention has excellent biocompatibility and degradability, can mediate cell migration, proliferation, differentiation and paracrine effect, and can speed up wound repair and improve wound healing effect.